Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of SB11 Prefilled Syringe in Neovascular AMD, RVO-Related Macular Oedema, or mCNV
2025-520599-24-00Phase 2Completed
- Sponsor
- Samsung Bioepis
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in exudative macular degeneration, retinal vein occlusion related macular edema (ME-RVO) and myopic choroidal neovascularisation (mCNV), sponsored by Samsung Bioepis. Primary endpoint: Percentage of successful task completions on all of 12 tasks. Started Jun 2025; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degenerationretinal vein occlusion related macular edema (ME-RVO)myopic choroidal neovascularisation (mCNV)
Beyond the preview
Go deeper on 2025-520599-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520599-24-00.